[
  {
    "ts": null,
    "headline": "Earnings live: Amazon, Reddit stocks sink to cap jam-packed earnings week",
    "summary": "The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far.",
    "url": "https://finnhub.io/api/news?id=4ce2a139137bda322b0547cf152bd87a737228e83484b9789b5b56c35d39951c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770413515,
      "headline": "Earnings live: Amazon, Reddit stocks sink to cap jam-packed earnings week",
      "id": 138379496,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The S&P 500 was on track for double-digit earnings growth, with more than half of companies having reported Q4 results so far.",
      "url": "https://finnhub.io/api/news?id=4ce2a139137bda322b0547cf152bd87a737228e83484b9789b5b56c35d39951c"
    }
  },
  {
    "ts": null,
    "headline": "Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling",
    "summary": "Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology. On February 2, 2026, U.S. District Judge Joshua D. Wolson denied Moderna’s request for summary judgment, saying the jury will have the choice whether Moderna’s COVID-19 vaccine, ...",
    "url": "https://finnhub.io/api/news?id=7eeb4c0770e68582175893f62f99c891f9c37ade478a98f84621615d060572c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770399180,
      "headline": "Moderna faces $5 billion mRNA patent lawsuit after 'Star Trek' ruling",
      "id": 138377072,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Behind the household COVID-19 name, Moderna, is facing a $5 billion patent-infringement lawsuit over vaccine technology. On February 2, 2026, U.S. District Judge Joshua D. Wolson denied Moderna’s request for summary judgment, saying the jury will have the choice whether Moderna’s COVID-19 vaccine, ...",
      "url": "https://finnhub.io/api/news?id=7eeb4c0770e68582175893f62f99c891f9c37ade478a98f84621615d060572c7"
    }
  },
  {
    "ts": null,
    "headline": "Roivant Sciences Q3 Earnings Call Highlights",
    "summary": "Roivant Sciences (NASDAQ:ROIV) executives highlighted new Phase II results for brepocitinib in cutaneous sarcoidosis, along with a set of broader clinical and corporate milestones, during the company’s third quarter fiscal 2025 earnings call covering the period ended December 31, 2025. Chief Execut",
    "url": "https://finnhub.io/api/news?id=028c2f6435250a2fc926b15a01f00d423f4399b1710d174d876f21027c5f271d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770390658,
      "headline": "Roivant Sciences Q3 Earnings Call Highlights",
      "id": 138375684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Roivant Sciences (NASDAQ:ROIV) executives highlighted new Phase II results for brepocitinib in cutaneous sarcoidosis, along with a set of broader clinical and corporate milestones, during the company’s third quarter fiscal 2025 earnings call covering the period ended December 31, 2025. Chief Execut",
      "url": "https://finnhub.io/api/news?id=028c2f6435250a2fc926b15a01f00d423f4399b1710d174d876f21027c5f271d"
    }
  },
  {
    "ts": null,
    "headline": "Immunovant Q3 Earnings Call Highlights",
    "summary": "Roivant reported third quarter fiscal 2025 financial results and highlighted new Phase 2 data for brepocitinib (BREPA) in cutaneous sarcoidosis, alongside a series of clinical and corporate updates that management described as evidence of “terrific execution and progress across the board.” CEO Matt",
    "url": "https://finnhub.io/api/news?id=f3d7ad16e2b76f952c5b6b82a0bd28f6beecd64b731c8c92dd7235c2fc48b9fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770390657,
      "headline": "Immunovant Q3 Earnings Call Highlights",
      "id": 138375685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Roivant reported third quarter fiscal 2025 financial results and highlighted new Phase 2 data for brepocitinib (BREPA) in cutaneous sarcoidosis, alongside a series of clinical and corporate updates that management described as evidence of “terrific execution and progress across the board.” CEO Matt",
      "url": "https://finnhub.io/api/news?id=f3d7ad16e2b76f952c5b6b82a0bd28f6beecd64b731c8c92dd7235c2fc48b9fe"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release",
    "summary": "Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=cd5b6b82abca4422ea6c4af477ae2b0a65d748adb208ffac4cb572d68a988226",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770390003,
      "headline": "Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release",
      "id": 138377073,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=cd5b6b82abca4422ea6c4af477ae2b0a65d748adb208ffac4cb572d68a988226"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock",
    "summary": "Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=976ece2583ab993e570ad91f3e30b7e37649e45f29714810b593c8f0a7260416",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770386403,
      "headline": "Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock",
      "id": 138375686,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=976ece2583ab993e570ad91f3e30b7e37649e45f29714810b593c8f0a7260416"
    }
  },
  {
    "ts": null,
    "headline": "Moderna (MRNA) Valuation Check As Rare Disease Deal And New Development Chief Refocus Growth Plans",
    "summary": "Moderna (MRNA) is back in focus after pairing a new rare disease collaboration on mRNA-3927 with Recordati with a leadership change, appointing immunotherapy veteran David Berman as Chief Development Officer. See our latest analysis for Moderna. Those moves come after a sharp rebound in Moderna’s 90 day share price return of 66.54% and a 32.44% gain year to date, even though the 3 year total shareholder return is still down 75.86%. This suggests sentiment has improved recently but remains...",
    "url": "https://finnhub.io/api/news?id=5645e93bc1b173f59114b8bcd7fdce581c7eb8b26a7970bb70389ab0179003b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770383175,
      "headline": "Moderna (MRNA) Valuation Check As Rare Disease Deal And New Development Chief Refocus Growth Plans",
      "id": 138374637,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna (MRNA) is back in focus after pairing a new rare disease collaboration on mRNA-3927 with Recordati with a leadership change, appointing immunotherapy veteran David Berman as Chief Development Officer. See our latest analysis for Moderna. Those moves come after a sharp rebound in Moderna’s 90 day share price return of 66.54% and a 32.44% gain year to date, even though the 3 year total shareholder return is still down 75.86%. This suggests sentiment has improved recently but remains...",
      "url": "https://finnhub.io/api/news?id=5645e93bc1b173f59114b8bcd7fdce581c7eb8b26a7970bb70389ab0179003b7"
    }
  }
]